DCC Vital to sell its generic drug units
Irish stock market-listed conglomerate DCC is to sell its generic pharmaceuticals businesses in Ireland and the UK to private equity firm Duke Street Capital.
The DCC Vital division has agreed a sale of the Kent Pharma and Athlone Laboratories units, including a manufacturing plant in Co Roscommon. There's not expected to be any impact on jobs.
Please log in or register with Independent.ie for free access to this article.
DCC bought Kent Pharma in 2012 for €71.2m.
It has owned the Athlone manufacturing plant, which employs around 200 staff, since 1992.
DCC said the disposal "will sharpen the strategic focus of DCC Vital, allowing it to concentrate on those areas where it has market-leading positions and sustainable competitive advantage, in particular in the sales, marketing and distribution of medical products in Britain and Ireland".
The transaction is expected to be completed in the third quarter of 2019.